Medindia

X

A Novel Oral Drug for the Treatment of Moderate to Severe Crohn's Disease Would Earn 40 Percent Patient Share in the U.S. and Europe

Thursday, April 15, 2010 Press Release J E 4
Advertisement
Abbott/Eisai's Humira Will Remain Decision Resources' Proprietary Clinical Gold Standard Through 2018, According to a New Report from Decision Resources

For more information, contact:

Decision Resources, Inc.

Christopher Comfort

781-296-2597

ccomfort@dresources.com

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
New Advisory Service From Decision Resources Keeps...
S
Varian Medical Systems Introduces Revolutionary Ne...